Analyst Price Targets — RCKT
Latest News for RCKT
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT - Get Free Report) has received a consensus rating of "Hold" from the ten analysts that are covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a sell rating, two have given a hold rating, four have issued a buy rating and one has issued a strong
RCKT records earnings growth in the second quarter. Kresladi launch preparations advance and RP-A501 safety findings support its next development steps.
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and devastating diseases, focused on inherited cardiovascular disorders, today reported financial and recent operational results for the second quarter ended June 30, 2026. “The second quarter of 2026 materially strengthened Rocket's position,…
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) on Monday shared a clinical safety update concerning the first three patients treated in its global, pivotal Phase 2 trial for Danon disease.
[url="]Rocket Pharmaceuticals, Inc.[/url] (Rocket or the Company) (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic m
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RCKT.
U.S. House Trading
No House trades found for RCKT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.